COVID-19: When Will Americans Need Third Shot According to Health Experts?

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
COVID-19: When Will Americans Need Third Shot According to Health Experts?

© Jeenah Moon / Getty Images News via Getty Images

The rate of the spread of COVID-19 has slowed across America. The country reported its lowest number of new infections in nearly a year for the week of May 17, representing a drop of 26% from the previous seven days.

Nevertheless, as of May 24, some 589,517 Americans had died of the disease, which is about 17% of the world’s total (a staggering 3.47 million). Reported cases have reached 33,137,938 in the U.S., but hospitalizations, which were over 100,000 a day during the peak wave, are less than a third of that today. (As of the end of 2020, these were the US cities with the highest COVID-19 death rates.)

Variants have become a large part of the conversation among public health officials and epidemiologists. One variant, first identified in the United Kingdom and known as B.1.1.7, is more transmissible than the strain that was dominant in the United States over most of the pandemic. 

The Centers for Disease Control and Prevention (CDC) also officially tracks these other variants: B.1.351, P.1, B.1.427 and B.1.429. Worries are that some may be more deadly than others and that vaccines may not protect against one or more variants. Scientists believe that new variants will continue to appear, some of which may originate in America and others that may come from overseas. The most recent one to be discovered, dubbed B.1.617.2, now dominant in India, may prove to be more transmissible even than B.1.1.7, the one that spurred the deadly surge in the UK this winter. 

The good news on our shores is that, at this point, according to The New York Times on May 24, some 49% of Americans have received at least one dose of a vaccine, and 39% are fully vaccinated. There has been a debate among scientists and doctors, however, about if and when people will need additional doses. Some of this has to do with how effective vaccines prove to be against the variants. Another major issue, of course, is that many Americans are still saying no to vaccination. (These are the states where the most people are refusing the COVID-19 vaccine.)

Click here to see when Americans will need the third shot according to health experts.

Scott Olson / Getty Images News via Getty Images

Will people need booster shots?

Pfizer CEO Albert Bourla has said that people will likely need a third dose of his vaccine, which is initially delivered in two doses, for continued effectiveness.

[in-text-ad]

Michael Ciaglo / Getty Images News via Getty Images

How soon will boosters be needed?

Albert Bourla of Pfizer says that boosters should probably be administered within 12 months of being vaccinated.

[recirclink id=882874]

Is it possible that boosters will be needed sooner?

To be on the safe side, both Pfizer and Moderna say that their trials show high levels of protection against COVID for six months after the second dose. That doesn’t mean the protection weakens after that point, only that it has only been verified that far.

So is it six months or a year?

The truth is, nobody knows for sure. “It could be more, it could be a little less,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research at a recent virtual press conference. “We’re gonna have to figure it out as we go.”

[in-text-ad-2]

Joe Raedle / Getty Images News via Getty Images

Will be need more boosters after the first one?

Probably. Dr. Ozlem Tureci, the chief medical officer of BioNTech, which helped Pfizer develop its vaccine, told CNBC that “people will need to get vaccinated against the coronavirus annually, like for the seasonal flu.”

Spencer Platt / Getty Images News via Getty Images

Why will boosters be needed?

Because, according to Dr. Tureci, it is expected that vaccine-induced immunity against the virus will decrease over time.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618